

January 28, 2019



XORTX to Present at NobleConXV Noble Capital Markets' 15th Annual Investor Conference

CALGARY, Alberta, Jan. 28, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (PKD), is pleased to announce that Dr. Allen Davidoff, XORTX's CEO will present at NobleConXV – Noble Capital Markets' 15th Annual Investor Conference at 9:30 am EST. A video webcast of the presentation will be available Tuesday, January 29th at the following link, <http://noble.mediasite.com/mediasite/Play/901e7d39fbf3435b93b1737e29673ea11d>. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek.com for 90 days following the event.

The NobleConXV conference is focused on emerging growth companies and attracts a wide range of investors from larger institutional portfolio managers to single family offices. Noble Capital Markets is an equity-research driven, full service, investment and merchant banking boutique focused on emerging growth companies.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com.

For further information, please contact:

Dr. Allen Davidoff, CEO
adavidoff@xortx.com or +1 403 455 7727

or Erik Matthews, Corporate Communications & Investor Relations
info@xortx.com or +1 747 203 5240

The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.



Source: XORTX Therapeutics Inc.